Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b.

[1]  J. Stockman.  Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1 , 2013 .

[2]  K. Chayama,et al.  Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b–infected null responders , 2012, Hepatology.

[3]  Anna Persson,et al.  Preliminary study of two antiviral agents for hepatitis C genotype 1. , 2012, The New England journal of medicine.

[4]  N. Hayashi,et al.  Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan. , 2012, Journal of hepatology.

[5]  Xin Huang,et al.  Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS‐790052 in Humans: In Vitro and In Vivo Correlations , 2011, Hepatology.

[6]  S. Locarnini,et al.  Hepatitis C virus resistance to protease inhibitors. , 2011, Journal of hepatology.

[7]  Sprint Investigators,et al.  Boceprevir for Untreated Chronic HCV Genotype 1 Infection , 2011 .

[8]  Stefan Zeuzem,et al.  Boceprevir for previously treated chronic HCV genotype 1 infection. , 2011, The New England journal of medicine.

[9]  J. Bukh,et al.  Recombinant HCV variants with NS5A from genotypes 1-7 have different sensitivities to an NS5A inhibitor but not interferon-α. , 2011, Gastroenterology.

[10]  M. Manns,et al.  Boceprevir for untreated chronic HCV genotype 1 infection. , 2011, The New England journal of medicine.

[11]  C. Schiffer,et al.  Drug resistance against HCV NS3/4A inhibitors is defined by the balance of substrate recognition versus inhibitor binding , 2010, Proceedings of the National Academy of Sciences.

[12]  Min Gao,et al.  Resistance Analysis of the Hepatitis C Virus NS5A Inhibitor BMS-790052 in an In Vitro Replicon System , 2010, Antimicrobial Agents and Chemotherapy.

[13]  Min Gao,et al.  Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect , 2010, Nature.

[14]  Christoph Sarrazin,et al.  Resistance to direct antiviral agents in patients with hepatitis C virus infection. , 2010, Gastroenterology.

[15]  Yoshiyuki Suzuki,et al.  Sustained virological response in a patient with chronic hepatitis C treated by monotherapy with the NS3-4A protease inhibitor telaprevir. , 2010, Journal of Clinical Virology.

[16]  Jean-Michel Pawlotsky,et al.  Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. , 2009, The New England journal of medicine.

[17]  I. James,et al.  Hepatitis C virus drug resistance and immune‐driven adaptations: Relevance to new antiviral therapy , 2009, Hepatology.

[18]  D. Harnois.  Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 Infection , 2009 .

[19]  Todd M. Allen,et al.  Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment‐naïve patients , 2008, Hepatology.

[20]  Tara L. Kieffer,et al.  Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects. , 2008, The Journal of infectious diseases.

[21]  H. Hotta,et al.  Sequence variation in hepatitis C virus nonstructural protein 5A predicts clinical outcome of pegylated interferon/ribavirin combination therapy , 2008, Hepatology.

[22]  S. Sauleda,et al.  Naturally occurring NS3-protease-inhibitor resistant mutant A156T in the liver of an untreated chronic hepatitis C patient. , 2008, Virology.

[23]  L. Seeff,et al.  Natural history of chronic hepatitis C , 2002, Hepatology.

[24]  J. Hoofnagle,et al.  Classification of chronic hepatitis: Diagnosis, grading and staging , 1994, Hepatology.